230 related articles for article (PubMed ID: 33312349)
1. Selection of new immunotherapy targets for NK/T cell lymphoma.
Lv K; Li X; Yu H; Chen X; Zhang M; Wu X
Am J Transl Res; 2020; 12(11):7034-7047. PubMed ID: 33312349
[TBL] [Abstract][Full Text] [Related]
2. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
Hu B; Oki Y
Front Oncol; 2018; 8():139. PubMed ID: 29761078
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
4. Treatment of extranodal NK/T-cell lymphoma: From past to future.
Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
[TBL] [Abstract][Full Text] [Related]
5. The landscape of new drugs in extranodal NK/T-cell lymphoma.
Wang L; Li LR; Zhang L; Wang JW
Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
[TBL] [Abstract][Full Text] [Related]
6. [Advances in immunotherapy of extranodal NK/T cell lymphoma].
Hao DQ; Li LQ; Li MC; Gong LL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Dec; 54(12):949-953. PubMed ID: 31887826
[TBL] [Abstract][Full Text] [Related]
7. Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?
Costa RO; Pereira J; Lage LAPC; Baiocchi OCG
Front Oncol; 2023; 13():1175545. PubMed ID: 37529691
[TBL] [Abstract][Full Text] [Related]
8. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.
Cho SG; Kim N; Sohn HJ; Lee SK; Oh ST; Lee HJ; Cho HI; Yim HW; Jung SE; Park G; Oh JH; Choi BO; Kim SW; Kim SW; Chung NG; Lee JW; Hong YS; Kim TG
Mol Ther; 2015 Aug; 23(8):1401-1409. PubMed ID: 26017177
[TBL] [Abstract][Full Text] [Related]
9. NK/T Cell Lymphoma: Updates in Therapy.
Suzuki R
Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
[TBL] [Abstract][Full Text] [Related]
10. EBV and the Pathogenesis of NK/T Cell Lymphoma.
Montes-Mojarro IA; Fend F; Quintanilla-Martinez L
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808787
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
12. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Kwong YL; Kim SJ; Tse E; Oh SY; Kwak JY; Eom HS; Do YR; Mun YC; Lee SR; Shin HJ; Suh C; Chuang SS; Lee YS; Lim ST; Izutsu K; Suzuki R; Relander T; d'Amore F; Schmitz N; Jaccard A; Kim WS
Ann Oncol; 2018 Jan; 29(1):256-263. PubMed ID: 29077846
[TBL] [Abstract][Full Text] [Related]
13. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
[TBL] [Abstract][Full Text] [Related]
14. IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma.
Wang L; Bi XW; Zhu YJ; He YZ; Lai QY; Xia ZJ; Cai QQ
Cancer Commun (Lond); 2018 Oct; 38(1):62. PubMed ID: 30340635
[TBL] [Abstract][Full Text] [Related]
15. Extranodal NK/T cell lymphoma.
Jeong SH
Blood Res; 2020 Jul; 55(S1):S63-S71. PubMed ID: 32719179
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
Tse E; Kwong YL
Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report.
Asif S; Begemann M; Bennett J; Fatima R; Masood A; Raza S
Mol Clin Oncol; 2019 Mar; 10(3):397-400. PubMed ID: 30847181
[TBL] [Abstract][Full Text] [Related]
18. NK/T-cell lymphomas.
Tse E; Kwong YL
Best Pract Res Clin Haematol; 2019 Sep; 32(3):253-261. PubMed ID: 31585625
[TBL] [Abstract][Full Text] [Related]
19. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
20. New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma.
Yi W; Yang T; Lin S; Hao R; Yu J; Wang Y; Tong X
Cancer Manag Res; 2022; 14():401-407. PubMed ID: 35115837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
